820 related articles for article (PubMed ID: 35512976)
1. Polycystic ovary syndrome: a "risk-enhancing" factor for cardiovascular disease.
Guan C; Zahid S; Minhas AS; Ouyang P; Vaught A; Baker VL; Michos ED
Fertil Steril; 2022 May; 117(5):924-935. PubMed ID: 35512976
[TBL] [Abstract][Full Text] [Related]
2. Polycystic ovary syndrome and cardiometabolic risk: Opportunities for cardiovascular disease prevention.
Osibogun O; Ogunmoroti O; Michos ED
Trends Cardiovasc Med; 2020 Oct; 30(7):399-404. PubMed ID: 31519403
[TBL] [Abstract][Full Text] [Related]
3. Subclinical cardiovascular disease and polycystic ovary syndrome.
Gomez JMD; VanHise K; Stachenfeld N; Chan JL; Merz NB; Shufelt C
Fertil Steril; 2022 May; 117(5):912-923. PubMed ID: 35512975
[TBL] [Abstract][Full Text] [Related]
4. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME - PART 2.
Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ;
Endocr Pract; 2015 Dec; 21(12):1415-26. PubMed ID: 26642102
[TBL] [Abstract][Full Text] [Related]
5. Polycystic Ovary Syndrome.
Azziz R
Obstet Gynecol; 2018 Aug; 132(2):321-336. PubMed ID: 29995717
[TBL] [Abstract][Full Text] [Related]
6. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1.
Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ;
Endocr Pract; 2015 Nov; 21(11):1291-300. PubMed ID: 26509855
[TBL] [Abstract][Full Text] [Related]
7. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society.
Wild RA; Carmina E; Diamanti-Kandarakis E; Dokras A; Escobar-Morreale HF; Futterweit W; Lobo R; Norman RJ; Talbott E; Dumesic DA
J Clin Endocrinol Metab; 2010 May; 95(5):2038-49. PubMed ID: 20375205
[TBL] [Abstract][Full Text] [Related]
8. Is There Really Increased Cardiovascular Morbidity in Women with Polycystic Ovary Syndrome?
Carmina E; Lobo RA
J Womens Health (Larchmt); 2018 Nov; 27(11):1385-1388. PubMed ID: 30199308
[TBL] [Abstract][Full Text] [Related]
9. Polycystic Ovary Syndrome, Insulin Resistance, and Cardiovascular Disease.
Dubey P; Reddy S; Sharma K; Johnson S; Hardy G; Dwivedi AK
Curr Cardiol Rep; 2024 Jun; 26(6):483-495. PubMed ID: 38568339
[TBL] [Abstract][Full Text] [Related]
10. Polycystic Ovarian Syndrome: a Risk Factor for Cardiovascular Disease.
Alvarez YR; Pico M; Ashokprabhu N; Abou-Amro K; Bailey S; Pung E; Oberholster E; Quesada O
Curr Atheroscler Rep; 2023 Dec; 25(12):1003-1011. PubMed ID: 38048007
[TBL] [Abstract][Full Text] [Related]
11. Heart health in polycystic ovary syndrome: time to act on the data.
Dokras A
Fertil Steril; 2022 May; 117(5):885-886. PubMed ID: 35512972
[TBL] [Abstract][Full Text] [Related]
12. Cardiometabolic biomarkers in women with polycystic ovary syndrome.
van der Ham K; Louwers YV; Laven JSE
Fertil Steril; 2022 May; 117(5):887-896. PubMed ID: 35512973
[TBL] [Abstract][Full Text] [Related]
13. Cardiometabolic Risk, Peripheral Arterial Disease and Cardiovascular Events in Polycystic Ovary Syndrome: Time to Implement Systematic Screening and Update the Management.
Janez A; Herman R; Poredos P; Mikhailidis DP; Blinc A; Sabovic M; Studen KB; Jezovnik MK; Schernthaner GH; Anagnostis P; Antignani PL; Jensterle M
Curr Vasc Pharmacol; 2023; 21(6):424-432. PubMed ID: 37779406
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular disease risk in offspring of polycystic ovary syndrome.
Shawky NM
Front Endocrinol (Lausanne); 2022; 13():977819. PubMed ID: 36531474
[TBL] [Abstract][Full Text] [Related]
15. Association of polycystic ovary syndrome with cardiovascular disease among female hospitalizations in the United States.
Dwivedi AK; Vishwakarma D; Dubey P; Reddy S
Eur J Endocrinol; 2023 Jun; 188(6):555-563. PubMed ID: 37307574
[TBL] [Abstract][Full Text] [Related]
16. The cardiovascular risk profile of middle-aged women with polycystic ovary syndrome.
Meun C; Gunning MN; Louwers YV; Peters H; Roos-Hesselink J; Roeters van Lennep J; Rueda Ochoa OL; Appelman Y; Lambalk N; Boersma E; Kavousi M; Fauser BC; Laven JS;
Clin Endocrinol (Oxf); 2020 Feb; 92(2):150-158. PubMed ID: 31638273
[TBL] [Abstract][Full Text] [Related]
17. The Prevalence of Polycystic Ovary Syndrome, Its Phenotypes and Cardio-Metabolic Features in a Community Sample of Iranian Population: Tehran Lipid and Glucose Study.
Farhadi-Azar M; Behboudi-Gandevani S; Rahmati M; Mahboobifard F; Khalili Pouya E; Ramezani Tehrani F; Azizi F
Front Endocrinol (Lausanne); 2022; 13():825528. PubMed ID: 35299965
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive Evaluation of Type 2 Diabetes and Cardiovascular Disease Risk Profiles in Reproductive-Age Women with Polycystic Ovary Syndrome: A Large Canadian Cohort.
Kazemi M; Pierson RA; Lujan ME; Chilibeck PD; McBreairty LE; Gordon JJ; Serrao SB; Zello GA; Chizen DR
J Obstet Gynaecol Can; 2019 Oct; 41(10):1453-1460. PubMed ID: 30712903
[TBL] [Abstract][Full Text] [Related]
19. Type 2 diabetes and cardiovascular disease in polycystic ovary syndrome: what are the risks and can they be reduced?
Tomlinson J; Millward A; Stenhouse E; Pinkney J
Diabet Med; 2010 May; 27(5):498-515. PubMed ID: 20536945
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome.
Glintborg D; Rubin KH; Nybo M; Abrahamsen B; Andersen M
Cardiovasc Diabetol; 2018 Mar; 17(1):37. PubMed ID: 29519249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
